Semax (5mg & 10mg Vial) Dosage Protocol
Quickstart Highlights
Semax is a synthetic heptapeptide analog of ACTH(4–10) developed in Russia and studied primarily for cognitive enhancement and neuroprotection[1][2]. While intranasal administration is most common in clinical literature, subcutaneous injection offers a convenient once‑daily alternative for research purposes[1][4]. This educational protocol presents a practical SC approach for both vial sizes with straightforward reconstitution for accurate insulin‑syringe measurements.
- Choose Your Vial: Select 5mg for general cognitive support or 10mg for extended protocols and cost-effectiveness.
- Typical daily range: 300–800 mcg once daily (gradual titration recommended). Higher doses (up to 6 mg) studied in post-stroke settings.
- Flexible Protocols: Daily or every-other-day subcutaneous injections; 4–8 week cycles common.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles[2][9].
Choose Your Vial Size
Select the vial size that best fits your research needs. Both options deliver the same high‑purity Semax peptide with different concentrations for dosing flexibility.
Semax 5mg Vial
- Best for: General cognitive support, testing tolerance, or short 4-week cycles
- Reconstitution: 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration
- Dosing at 1.67 mg/mL: 1 unit = 0.01 mL ≈ 16.7 mcg
- 300 mcg dose: 18 units (0.18 mL)
- 500 mcg dose: 30 units (0.30 mL)
- Vials needed for 4-week cycle @ 0.5 mg/day: ≈ 3 vials
Semax 10mg Vial
- Best for: Extended protocols, cost-effective bulk research, or higher dose regimens
- Reconstitution: 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration
- Dosing at 3.33 mg/mL: 1 unit = 0.01 mL ≈ 33.3 mcg
- 300 mcg dose: 9 units (0.09 mL)
- 500 mcg dose: 15 units (0.15 mL)
- Vials needed for 8-week cycle @ 0.5-0.8 mg/day: ≈ 4 vials
- For ≤10‑unit administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing across both vial sizes
Standard / Gradual Approach
| Week | Daily Dose (mcg) | 5mg Vial (3.0 mL) | 10mg Vial (3.0 mL) |
|---|---|---|---|
| Weeks 1–2 | 300 mcg (0.3 mg) | 18 units (0.18 mL) | 9 units (0.09 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 30 units (0.30 mL) | 15 units (0.15 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 36 units (0.36 mL) | 18 units (0.18 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 48 units (0.48 mL) | 24 units (0.24 mL) |
Frequency: Inject once daily subcutaneously[1][4]. This schedule uses the largest practical dilution (3.0 mL) to ensure per‑injection volumes are accurate and manageable. Most human nootropic studies use intranasal dosing in the range of 400–900 mcg/day divided into multiple administrations[2][3]; this SC protocol delivers comparable total daily amounts in a single injection for convenience.
Advanced / Post-Stroke Approach
| Days | Daily Dose (mg) | 5mg Vial (1.0 mL) | 10mg Vial (1.0 mL) |
|---|---|---|---|
| Days 1–10 | 6 mg | 120 units (1.2 mL)* *Requires >1 vial | 60 units (0.60 mL) |
Note: This higher-dose protocol (6 mg/day) is referenced in post-stroke research[3]. Reconstitute with 1.0 mL to create a more concentrated solution for easier measurement. For 5mg vials: 1 mL creates 5 mg/mL solution (50 mcg/unit); for 10mg vials: 1 mL creates 10 mg/mL solution (100 mcg/unit). Doses exceeding syringe capacity require careful planning.
Reconstitution Steps
- Draw appropriate bacteriostatic water volume:
- Standard approach: 3.0 mL for both vial sizes
- Advanced approach: 1.0 mL for concentrated dosing
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light[2].
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration at standard dosing ranges.
| Item | Semax 5mg Vials | Semax 10mg Vials |
|---|---|---|
| Peptide Vials (8 weeks @ 0.5-0.8 mg/day) | ≈ 9 vials | ≈ 4 vials |
| Peptide Vials (12 weeks @ 0.5-0.8 mg/day) | ≈ 14 vials | ≈ 6 vials |
| Peptide Vials (16 weeks @ 0.5-0.8 mg/day) | ≈ 18 vials | ≈ 8 vials |
| Peptide Vials (10-day advanced @ 6 mg/day) | ≈ 12 vials | ≈ 6 vials |
| Bacteriostatic Water (per vial reconstitution) | 3.0 mL (standard) 1.0 mL (advanced) | 3.0 mL (standard) 1.0 mL (advanced) |
| Insulin Syringes (U‑100) | 56 syringes (8 weeks) 84 syringes (12 weeks) 112 syringes (16 weeks) | 56 syringes (8 weeks) 84 syringes (12 weeks) 112 syringes (16 weeks) |
| Alcohol Swabs (2 per injection) | 112 swabs (8 weeks) 168 swabs (12 weeks) 224 swabs (16 weeks) | 112 swabs (8 weeks) 168 swabs (12 weeks) 224 swabs (16 weeks) |
Protocol Overview
Concise summary of the once‑daily SC regimen.
- Goal: Support cognitive function, attention, and neuroprotective pathways studied in clinical literature[2][5].
- Schedule: Daily subcutaneous injections for 4–8 weeks (extend to 12–16 weeks with cycling if desired)[4].
- Dose Range: 300–800 mcg daily (standard); up to 6 mg daily (advanced/post-stroke).
- Reconstitution: 3.0 mL per vial for standard dosing; 1.0 mL for concentrated advanced dosing.
- Storage: Lyophilized frozen; reconstituted refrigerated; use within 30 days[2][9].
Dosing Protocol
Suggested daily titration approach.
- Start: 300 mcg daily; increase by ~100–200 mcg every 1–2 weeks as tolerated.
- Standard Target: 600–800 mcg daily by Weeks 5–8; adjust based on individual response.
- Advanced Target: 6 mg daily for short 10-day courses (post-stroke research).
- Frequency: Once per day (subcutaneous)[1][4] or every-other-day as needed.
- Cycle Length: 4–8 weeks continuous; optional extension to 12–16 weeks with off‑periods[4].
- Timing: Morning injections common; rotate injection sites systematically.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions[9]; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for up to 30 days[2][9]; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- Protect from light; wrap vials in foil or store in an opaque container[9].
Important Notes
Practical considerations for consistency and safety across both vial sizes.
- Use new sterile insulin syringes for each injection; dispose in a sharps container[7].
- Rotate injection sites (abdomen, thighs, upper arms) at least 1–2 inches from previous sites to reduce local irritation[7].
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose, injection time, and site rotation to maintain consistency.
- Most human data are for 4–8 weeks of continuous use; longer protocols should incorporate rest periods[4].
- For advanced dosing (>1 mg), ensure syringe capacity accommodates required volume; may need multiple injections.
How This Works
Semax is a synthetic analog of the ACTH(4–10) fragment with a C‑terminal Pro‑Gly‑Pro tripeptide extension that enhances metabolic stability[1][5]. Clinical and preclinical literature suggest it modulates brain‑derived neurotrophic factor (BDNF) expression, enhances cholinergic and dopaminergic neurotransmission, and exhibits neuroprotective properties in models of cerebrovascular and cognitive impairment[2][5]. Human studies in Russia have employed Semax for cognitive support in conditions ranging from mild cognitive impairment to acute stroke recovery, typically using intranasal administration[2][3][6]. Subcutaneous delivery offers an alternative route with potentially more sustained systemic absorption[1][4].
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- May support attention, memory consolidation, and learning in clinical populations with cognitive deficits[2][5].
- Studied in neurological conditions including stroke, traumatic brain injury, and optic neuropathy with favorable safety profiles in month‑long human trials[2][3][6].
- Provides neuroprotective effects that could aid in stroke recovery protocols.
- Generally well tolerated; intranasal administration may cause minor nasal irritation; subcutaneous injection may produce mild injection‑site reactions (redness, itching).
- No significant elevations in cortisol or other adverse endocrine effects reported in clinical studies[2].
- Possible mild side effects include headache, restlessness, or slight blood pressure fluctuations; rarely, injection-site irritation or allergic reactions could occur.
- Effects are dose‑dependent; titration helps identify the minimum effective dose for individual response[2].
Lifestyle Factors
Complementary strategies for optimal cognitive support.
- Maintain consistent sleep schedules and prioritize 7–9 hours of quality sleep per night.
- Engage in regular aerobic exercise and cognitive training to reinforce neuroplastic adaptations.
- Follow a balanced diet rich in omega‑3 fatty acids, antioxidants, and micronutrients that support brain health.
- Manage stress through mindfulness, meditation, or other relaxation techniques.
- Stay mentally active with challenging tasks, learning new skills, and social engagement.
- Adopt a balanced diet rich in antioxidants and essential nutrients for neurological health.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[7][8][9].
- Clean the vial stopper and injection site with alcohol swabs; allow to dry completely.
- Pinch a 1–2 inch skinfold; insert the needle at 45–90° into subcutaneous tissue (angle depends on needle length and fat layer)[7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7][8].
- Withdraw the needle at the same angle; apply gentle pressure with clean gauze (do not rub vigorously)[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy or tissue irritation; maintain at least 1–2 inches between injection sites[7].
- Dispose of used syringes immediately in a proper sharps container[7].
Recommended Source
We recommend Legion Peptides for high‑purity Semax in both vial sizes (5mg and 10mg).
Why Legion Peptides?
- High‑purity, third‑party‑tested lots with batch certificates of analysis (COAs).
- Consistent, ISO‑aligned handling and documentation for research‑grade peptides.
- Reliable fulfillment with proper cold‑chain protocols to maintain peptide integrity.
- Verifies ≥99% purity through independent lab testing and follows rigorous manufacturing standards.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Semax is for research use only and not intended for human consumption. Always consult with qualified healthcare professionals before considering any peptide protocol. This guide is for educational purposes only.
References
- Neuroscience and Behavioral Physiology (Springer) — Comparative study of Semax administration routes (intranasal vs. subcutaneous) in animal models
- Vidal Drug Reference (Russia) — Official prescribing information for Semax 0.1% intranasal drops; human dosing guidelines and administration schedules
- Journal of Neurology and Psychiatry (Russia) — Clinical trial of Semax in ischemic stroke patients (6,000 mcg/day intranasal protocol with cycling)
- Peptides.org — Semax dosage overview, cycling recommendations, and protocol duration guidance
- Journal of Higher Nervous Activity (Russia) — Early human study introducing Semax's nootropic properties and mechanism of action
- Vestnik Oftalmologii (Russian Ophthalmology Journal) — Human study of Semax in glaucomatous optic neuropathy; 30‑day safety data
- Johns Hopkins Arthritis Center — Clinical guide to subcutaneous injection technique (preparation, angle, site rotation)
- CDC — Vaccine administration guidelines for subcutaneous injections (angle, no aspiration)
- Pharmaceutics (MDPI) — Overview of Russian peptide drugs including Semax; formulation stability and storage considerations
